Phase IIb, a double-blind, placebo-controlled clinical trial to investigate the safety and efficacy of MDMA-assisted psychotherapy for Alcohol Use Disorder

This trial builds on the results of a Phase I study from the same research group. In the open-label study, MDMA-assisted psychotherapy was well-tolerated and safe to use. The average consumption of alcohol nine months later was 18.7 units, versus 130.6 units before the detox.

Awakn Life Sciences is planning to conduct a Phase II study exploring the safety and efficacy of MDMA-assisted psychotherapy for Alcohol Use Disorder (AUD).

Topic Addiction Alcohol Use Disorder
Compound MDMA
Country United Kingdom
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Awakn Life Sciences
AWAKN Life Sciences aims to bring psychedelics therapy to the UK. Under this company fall three arms; psychedelic research, clinic platform, and practitioner training.

Imperial College London
The Centre for Psychedelic Research studies the action (in the brain) and clinical use of psychedelics, with a focus on depression.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.